Metformin Mimics Exercise-Related Metabolic Signals in Prostate Cancer Patients, Study Finds

New research finds metformin raises Lac-Phe levels, a molecule tied to weight control, mimicking exercise effects for prostate cancer patients with limited mobility.

By: AXL Media

Published: Apr 6, 2026, 9:02 AM EDT

Source: Information for this report was sourced from the University of Miami Miller School of Medicine and the journal EMBO Molecular Medicine (2026).

Bridging the Gap Between Exercise and Pharmacology

Exercise is a cornerstone of recovery during cancer treatment, aiding in weight regulation and cardiovascular health. However, for many prostate cancer patients, hormone therapy and advanced disease cause fatigue and pain that make physical activity nearly impossible. A new study published in EMBO Molecular Medicine on April 6, 2026, suggests that the drug metformin may help bridge this gap by activating internal metabolic pathways usually reserved for physical exertion.

The Role of the "Exercise Molecule" Lac-Phe

At the heart of the study is N-lactoyl-phenylalanine (Lac-Phe), a molecule produced when lactate (from exertion) combines with the amino acid phenylalanine. Scientists have long noted that Lac-Phe levels spike after strenuous exercise, leading to suppressed appetite and improved weight control. The researchers at Sylvester Comprehensive Cancer Center discovered that metformin raises Lac-Phe levels in prostate cancer patients to a degree that approximates the levels seen after intense workouts—even when the patients remained inactive.

Metabolic Support During Hormone Therapy

Prostate cancer treatments, particularly hormone-based therapies, often disrupt a patient’s metabolism, leading to: